BMS-986235(LAR-1219)是一种选择性、具有口服活性的甲酰肽受体2(FPR2)激动剂,对hFPR2和mFPR2的EC50分别为0.41nM和3.4nM。BMS-986235具有预防心力衰竭的潜力。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1].
BMS-986235 (LAR-1219) inhibits neutrophil chemotaxis and stimulats macrophage phagocytosis, key end points to promote resolution of inflammation[1].
BMS-986235 (LAR-1219) (0.3 mg/kg; p.o.; daily for 24 days) can attenuate left ventricle and global cardiac remodeling after left anterior descending (LAD) in mice[1].BMS-986235 (1 mg/kg; p.o.) treatment shows the Cmax, T1/2, AUC0-inf, and bioavailability (BA) values of 160 nmol/L, 0.68 hours,120 nmol/L?h, and 24%, respectively[1]. Animal Model: Male C57BL/6 mice[1]
[1]. Asahina Y, et al. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure [published online ahead of print, 2020 May 24]. J Med Chem. 2020;10.1021/acs.jmedchem.9b02101.
Quinupristin-Dalfopristin Complex (mesylate)
¥2560.00 ¥3200.00
Tankyrase Inhibitors (TNKS) 49
¥1320.00 ¥1650.00
没有评价数据